{"DataElement":{"publicId":"7847163","version":"1","preferredName":"Lorlatinib Agent Dose Reduced Administered Day Count","preferredDefinition":"An indicator of number in days Lorlatinib agent dose was reduced.","longName":"LORLB_DS_RDC_DY_CT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7847162","version":"1","preferredName":"Lorlatinib Agent Dose Reduced Administered","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount._The act of having given something (e.g., a medication or test).","longName":"6199780v1.0:7847160v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6199780","version":"1","preferredName":"Lorlatinib Agent","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C113655:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorlatinib","conceptCode":"C113655","definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FC2277-BA3F-2DAE-E053-F662850AC025","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"KRYSTKIA","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7847160","version":"1","preferredName":"Dose Reduced Administered","preferredDefinition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.:The act of having given something (e.g., a medication or test).","longName":"C49505:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Reduced","conceptCode":"C49505","definition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D20AE626-C417-47C0-E053-4EBD850A4A30","latestVersionIndicator":"Yes","beginDate":"2021-11-30","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-11-30","modifiedBy":"ONEDATA","dateModified":"2021-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D20AE626-C428-47C0-E053-4EBD850A4A30","latestVersionIndicator":"Yes","beginDate":"2021-11-30","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-11-30","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018594","version":"1","preferredName":"Day Count","preferredDefinition":"the quantity of days.","longName":"D_CT","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207941","version":"1","preferredName":"Day Count","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.:To determine the number or amount of something; the result of this activity.","longName":"C25301:C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-35FE-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66ACE83-B97C-5040-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"CAMPBELB","dateModified":"2017-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Number of day(s) Lorlatinib d","type":"Preferred Question Text","description":"Number of day(s) Lorlatinib dose was reduced:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D20A973F-7865-39BF-E053-4EBD850A4CC6","latestVersionIndicator":"Yes","beginDate":"2021-11-30","endDate":null,"createdBy":"LAMEMIL","dateCreated":"2021-11-30","modifiedBy":"KUMMEROA","dateModified":"2022-02-02","changeDescription":"2022-2-2 ak Released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}